{
  "drug_results": [
    {
      "components": [
        "Abiraterone"
      ],
      "drug": "Abiraterone",
      "extractions": {
        "Abiraterone": {
          "confidence_score": 1.0,
          "drug_classes": [
            "CYP17 Inhibitor"
          ],
          "drug_name": "Abiraterone",
          "extraction_details": [
            {
              "class_type": "MoA",
              "evidence": "ZYTIGA is a CYP17 inhibitor indicated in combination with prednisone",
              "extracted_text": "CYP17 inhibitor",
              "normalized_form": "CYP17 Inhibitor",
              "rules_applied": [
                "Rule 11: Include biological target (CYP17)",
                "Rule 13: Add Inhibitor as drug class",
                "Rule 3: Apply Title Case"
              ],
              "source": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513"
            }
          ],
          "extraction_method": "tavily",
          "reasoning": "The abstract title mentions the drug but does not describe its class. Search results (Results 1 and 2) explicitly state that Abiraterone is a 'CYP17 inhibitor'. This is a specific enzymatic target and mechanism. Rule 11 requires including the biological target (CYP17) with the inhibitor modality. Rule 13 supports adding 'Inhibitor'. Rule 3 requires Title Case. The extracted class is 'CYP17 Inhibitor'.",
          "selected_sources": [
            "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513",
            "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b36bff33-595e-4827-9a73-85c6954c314c"
          ],
          "success": true
        }
      },
      "selections": {
        "Abiraterone": {
          "drug_name": "Abiraterone",
          "reasoning": "Only one unique class was extracted. No selection needed.",
          "selected_drug_classes": [
            "CYP17 Inhibitor"
          ]
        }
      }
    },
    {
      "components": [
        "Olaparib"
      ],
      "drug": "Olaparib",
      "extractions": {
        "Olaparib": {
          "confidence_score": 1.0,
          "drug_classes": [
            "PARP Inhibitor"
          ],
          "drug_name": "Olaparib",
          "extraction_details": [
            {
              "class_type": "MoA",
              "evidence": "Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes",
              "extracted_text": "inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes",
              "normalized_form": "PARP Inhibitor",
              "rules_applied": [
                "Rule 11: Include biological target (PARP)",
                "Rule 13: Add Inhibitor as a drug class",
                "Rule 3: Maintain Title Case"
              ],
              "source": "https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib"
            },
            {
              "class_type": "MoA",
              "evidence": "Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor",
              "extracted_text": "poly (ADP-ribose) polymerase (PARP) inhibitor",
              "normalized_form": "PARP Inhibitor",
              "rules_applied": [
                "Rule 11: Include biological target (PARP)",
                "Rule 13: Add Inhibitor as a drug class",
                "Rule 3: Maintain Title Case"
              ],
              "source": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf"
            }
          ],
          "extraction_method": "tavily",
          "reasoning": "The abstract title mentions Olaparib but does not explicitly state its drug class. Therefore, the search results were examined. The search results consistently describe Olaparib as a poly (ADP-ribose) polymerase (PARP) inhibitor. Specifically, Result 1 from PubChem states it is a 'selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes' and 'DrugBank: Olaparib is a Poly(ADP-Ribose) Polymerase Inhibitor'. Result 2 and Result 3 (FDA labels) also define it as a 'poly (ADP-ribose) polymerase (PARP) inhibitor'. Following Rule 11 and Rule 13, this is extracted as 'PARP Inhibitor'. Rule 13 states to add 'Inhibitor' when blockade/inhibitor terms are used. Rule 11 requires including the biological target (PARP).",
          "selected_sources": [
            "https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib",
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf",
            "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/206162Orig1s007.pdf"
          ],
          "success": true
        }
      },
      "selections": {
        "Olaparib": {
          "drug_name": "Olaparib",
          "reasoning": "Only one unique class was extracted. No selection needed.",
          "selected_drug_classes": [
            "PARP Inhibitor"
          ]
        }
      }
    }
  ],
  "drug_selections": [
    {
      "drug_name": "Abiraterone",
      "selected_classes": [
        "CYP17 Inhibitor"
      ]
    },
    {
      "drug_name": "Olaparib",
      "selected_classes": [
        "PARP Inhibitor"
      ]
    }
  ],
  "extraction_results": {
    "Abiraterone": {
      "confidence_score": 1.0,
      "drug_classes": [
        "CYP17 Inhibitor"
      ],
      "drug_name": "Abiraterone",
      "extraction_details": [
        {
          "class_type": "MoA",
          "evidence": "ZYTIGA is a CYP17 inhibitor indicated in combination with prednisone",
          "extracted_text": "CYP17 inhibitor",
          "normalized_form": "CYP17 Inhibitor",
          "rules_applied": [
            "Rule 11: Include biological target (CYP17)",
            "Rule 13: Add Inhibitor as drug class",
            "Rule 3: Apply Title Case"
          ],
          "source": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513"
        }
      ],
      "extraction_method": "tavily",
      "reasoning": "The abstract title mentions the drug but does not describe its class. Search results (Results 1 and 2) explicitly state that Abiraterone is a 'CYP17 inhibitor'. This is a specific enzymatic target and mechanism. Rule 11 requires including the biological target (CYP17) with the inhibitor modality. Rule 13 supports adding 'Inhibitor'. Rule 3 requires Title Case. The extracted class is 'CYP17 Inhibitor'.",
      "selected_sources": [
        "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4e338e89-3cf2-48eb-b6e2-a06c608c6513",
        "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b36bff33-595e-4827-9a73-85c6954c314c"
      ],
      "success": true
    },
    "Olaparib": {
      "confidence_score": 1.0,
      "drug_classes": [
        "PARP Inhibitor"
      ],
      "drug_name": "Olaparib",
      "extraction_details": [
        {
          "class_type": "MoA",
          "evidence": "Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes",
          "extracted_text": "inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes",
          "normalized_form": "PARP Inhibitor",
          "rules_applied": [
            "Rule 11: Include biological target (PARP)",
            "Rule 13: Add Inhibitor as a drug class",
            "Rule 3: Maintain Title Case"
          ],
          "source": "https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib"
        },
        {
          "class_type": "MoA",
          "evidence": "Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor",
          "extracted_text": "poly (ADP-ribose) polymerase (PARP) inhibitor",
          "normalized_form": "PARP Inhibitor",
          "rules_applied": [
            "Rule 11: Include biological target (PARP)",
            "Rule 13: Add Inhibitor as a drug class",
            "Rule 3: Maintain Title Case"
          ],
          "source": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf"
        }
      ],
      "extraction_method": "tavily",
      "reasoning": "The abstract title mentions Olaparib but does not explicitly state its drug class. Therefore, the search results were examined. The search results consistently describe Olaparib as a poly (ADP-ribose) polymerase (PARP) inhibitor. Specifically, Result 1 from PubChem states it is a 'selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes' and 'DrugBank: Olaparib is a Poly(ADP-Ribose) Polymerase Inhibitor'. Result 2 and Result 3 (FDA labels) also define it as a 'poly (ADP-ribose) polymerase (PARP) inhibitor'. Following Rule 11 and Rule 13, this is extracted as 'PARP Inhibitor'. Rule 13 states to add 'Inhibitor' when blockade/inhibitor terms are used. Rule 11 requires including the biological target (PARP).",
      "selected_sources": [
        "https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib",
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf",
        "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/206162Orig1s007.pdf"
      ],
      "success": true
    }
  }
}